Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

[Articles] The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

20:41 EDT 27 Jun 2013 | The Lancet

A recommended phase 2 dose of 300 mg/day niraparib is well tolerated. Niraparib should be further assessed in inherited and sporadic cancers with homologous recombination DNA repair defects and to target PARP-mediated transcription in cancer.

Original Article: [Articles] The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

NEXT ARTICLE

More From BioPortfolio on "[Articles] The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial"

Search BioPortfolio: